ArticleMolecular nutrition & food research2018
Dietary Mannan Oligosaccharides Modulate Gut Microbiota, Increase Fecal Bile Acid Excretion, and Decrease Plasma Cholesterol and Atherosclerosis Development.
Article in Molecular nutrition & food research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 91 citations in OpenAlex.
- Bacteroides ovatus Has the Potential to Be a Next-Generation Probiotic Strain.Probiotics and antimicrobial proteins · 2026Review
- Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver.Science China. Life sciences · 2026Article
- Gut Microbiota-Derived Metabolites in Atherosclerosis: Pathways, Biomarkers, and Targets.International journal of molecular sciences · 2025Review
- Different carbohydrate sources in dog foods supported overall health and cardiac function: an 18-mo prospective study in healthy adult dogs.Journal of animal science · 2025Article
- Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
- Dietary β-mannanase reduced post-weaning diarrhea of pigs by positively modulating gut microbiota and attenuating systemic immune responses.Animal microbiome · 2024Article
- Regulations of Citrus Pectin Oligosaccharide on Cholesterol Metabolism: Insights from Integrative Analysis of Gut Microbiota and Metabolites.Nutrients · 2024Article
- Impact of the gut microbiome on atherosclerosis.mLife · 2024Review
- Neoagarotetraose Alleviates Atherosclerosis via Modulating Cholesterol and Bile Acid Metabolism in ApoENutrients · 2024Article
- Gut Mycobiome and Asthma.Journal of fungi (Basel, Switzerland) · 2024Review
- Exploring of gut microbiota features in dyslipidemia and chronic coronary syndrome patients undergoing coronary angiography.Frontiers in microbiology · 2024Article
- Article
- Oligosaccharides as Potential Regulators of Gut Microbiota and Intestinal Health in Post-COVID-19 Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Prevention of Metabolic Syndrome by Phytochemicals and Vitamin D.International journal of molecular sciences · 2023Review
- Oligosaccharides and diet-related dilated cardiomyopathy in beagles.Frontiers in veterinary science · 2023Article
- Gut microbiota derived bile acid metabolites maintain the homeostasis of gut and systemic immunity.Frontiers in immunology · 2023Review
- Role of Gut Microbiome in Atherosclerosis: Molecular and Therapeutic Aspects.Current cardiology reviews · 2023Review
- Evaluation of Full-Length Versus V4-Region 16S rRNA Sequencing for Phylogenetic Analysis of Mouse Intestinal Microbiota After a Dietary Intervention.Current microbiology · 2022Article
- Tackling Atherosclerosis via Selected Nutrition.International journal of molecular sciences · 2022Review
- An Antioxidant Supplement Function Exploration: Rescue of Intestinal Structure Injury by Mannan Oligosaccharides afterAntioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
scopeMannan oligosaccharides (MOS) have proven effective at improving growth performance, while also reducing hyperlipidemia and inflammation. As atherosclerosis is accelerated both by hyperlipidemia and inflammation, we aim to determine the effect of dietary MOS on atherosclerosis development in hyperlipidemic ApoE*3-Leiden.CETP (E3L.CETP) mice, a well-established model for human-like lipoprotein metabolism. METHODS AND
resultsFemale E3L.CETP mice were fed a high-cholesterol diet, with or without 1% MOS for 14 weeks. MOS substantially decreased atherosclerotic lesions up to 54%, as assessed in the valve area of the aortic root. In blood, IL-1RA, monocyte subtypes, lipids, and bile acids (BAs) were not affected by MOS. Gut microbiota composition was determined using 16S rRNA gene sequencing and MOS increased the abundance of cecal Bacteroides ovatus. MOS did not affect fecal excretion of cholesterol, but increased fecal BAs as well as butyrate in cecum as determined by gas chromatography mass spectrometry.
conclusionMOS decreased the onset of atherosclerosis development via lowering of plasma cholesterol levels. These effects were accompanied by increased cecal butyrate and fecal excretion of BAs, presumably mediated via interactions of MOS with the gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.